Clinical Trial Update: Regorafenib in Subjects With Gastrointestinal Stromal Tumors (GIST) Who Have Progressed After Standard Therapy (Managed Access Program)

View source ↗

Summary

The Bayer-managed access program for regorafenib in gastrointestinal stromal tumors (GIST) that progressed after standard therapy is no longer available.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastrointestinal Stromal Tumors

Drugs mentioned

• Stivarga (regorafenib)

Snippet

Sponsor: Bayer | Conditions: Gastrointestinal Stromal Tumors | Status: NO_LONGER_AVAILABLE